Quantum BioPharma Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company's lead drug candidate, Lucid-MS, and its commercial product, unbuzzd(TM). Durkacz emphasized that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage, an area he believes remains unmet by currently available treatments.

Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of MS. The therapy is currently in Phase 1 testing in healthy volunteers, with an upcoming Phase 2 clinical trial that will be the first study to evaluate the drug candidate in MS patients. This advancement could represent a significant step forward in treating the neurodegenerative condition.

Durkacz also highlighted Quantum BioPharma's commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood alcohol metabolism and is currently available in the U.S. market. The product is sold by Unbuzzd Wellness Inc., a company spun out from Quantum BioPharma. Quantum retains a 19.84% ownership stake in Unbuzzd (as of March 31, 2026) and is entitled to royalty payments of 7% of sales from unbuzzd(TM) until payments total $250 million, after which the royalty drops to 3% in perpetuity. Additionally, Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.

The company's focus on both a high-potential drug candidate and a revenue-generating consumer product positions it uniquely in the biopharmaceutical space. The upcoming Phase 2 trial for Lucid-MS will be a critical milestone, potentially providing data on its efficacy in MS patients. Meanwhile, unbuzzd(TM) offers a steady revenue stream through royalties and equity, supporting the company's broader research and development efforts.

Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. For more information, visit the company's newsroom at https://ibn.fm/QNTM.